Herpesviruses Reactivate in Acute and Long COVID-19

Chronic reactivation of distinct herpesviruses and anelloviruses has been identified in individuals experiencing both acute and long COVID-19. This reactivation tracks with disease severity, inflammation levels, and patient outcomes, according to a study published online in Nature on August 5, 2026. The findings suggest the presence of immune signatures that hold prognostic potential for understanding and managing the multifaceted impacts of SARS-CoV-2 infection.

The research focused on analyzing viral reactivation patterns in a cohort of patients with COVID-19. Herpesviruses, a family of viruses that includes Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6 (HHV-6), are known for their ability to remain dormant in the body for extended periods and reactivate under conditions of immune suppression or stress. Anelloviruses are another group of ubiquitous, often asymptomatic viruses that can also exhibit altered replication dynamics during illness.

By examining viral loads and reactivation markers in these patients, the study established a correlation between the presence and activity of these specific viruses and the clinical presentation of COVID-19. Higher levels of reactivation were observed in individuals with more severe acute illness and those who subsequently developed long COVID symptoms. This suggests that the immune system's response to SARS-CoV-2 may be compromised or altered in a way that permits the resurgence of latent viral infections.

Furthermore, the study linked viral reactivation to systemic inflammation. Inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), were found to be elevated in patients exhibiting significant herpesvirus and anellovirus reactivation. This interplay between viral activity and the host's inflammatory response could be a key driver of the persistent symptoms associated with long COVID, which can include fatigue, cognitive dysfunction, and respiratory issues. The identification of these immune signatures provides a potential avenue for developing diagnostic tools or therapeutic strategies aimed at mitigating the long-term consequences of COVID-19 by targeting viral reactivation and associated inflammation. The study's publication in Nature, a leading scientific journal, underscores the significance of these findings in the ongoing effort to understand the complex pathophysiology of COVID-19 and its sequelae. The doi for the publication is 10.1038/s41586-026-10740-z.